329 related articles for article (PubMed ID: 28718430)
1. Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.
Gargalionis AN; Papavassiliou AG
Trends Cancer; 2017 Mar; 3(3):166-168. PubMed ID: 28718430
[TBL] [Abstract][Full Text] [Related]
2. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer.
Ding Y; Li W; Wang K; Xu C; Hao M; Ding L
Biomed Res Int; 2020; 2020():6843180. PubMed ID: 32258135
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy challenge and hope in colorectal cancer.
Burz C; Rosca A; Pop VV; Buiga R; Aldea C; Samasca G; Silaghi C; Sur D; Lupan I; Pricopie A
Expert Rev Mol Diagn; 2019 Apr; 19(4):341-348. PubMed ID: 30943811
[TBL] [Abstract][Full Text] [Related]
5. Role of circulating tumor DNA in the management of patients with colorectal cancer.
Moati E; Taly V; Didelot A; Perkins G; Blons H; Taieb J; Laurent-Puig P; Zaanan A
Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):396-402. PubMed ID: 29627453
[TBL] [Abstract][Full Text] [Related]
6. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
7. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
8. [Possibilities of liquid biopsy in gastric cancer].
Zakharenko AA; Zaitsev DA; Belyaev MA; Trushin AA; Ten OA; Natkha AS
Vopr Onkol; 2016; 62(4):379-85. PubMed ID: 30474943
[TBL] [Abstract][Full Text] [Related]
9. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
10. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA as a marker of minimal residual disease in colorectal cancer.
Kopetz S
Clin Adv Hematol Oncol; 2020 Dec; 18(12):791-792. PubMed ID: 33406055
[No Abstract] [Full Text] [Related]
12. "Liquid Biopsy" - Is it a Feasible Option in Colorectal Cancer?
Scripcariu V; Scripcariu DV; Filip B; Gavrilescu MM; Muşină AM; Volovăţ C
Chirurgia (Bucur); 2019; 114(2):162-166. PubMed ID: 31060647
[TBL] [Abstract][Full Text] [Related]
13. Advances in Cancer Therapy: Liquid Biopsy.
Marmé D
Oncol Res Treat; 2017; 40(7-8):402-403. PubMed ID: 28728143
[No Abstract] [Full Text] [Related]
14. Liquid biopsies: Potential and challenges.
Heidrich I; Ačkar L; Mossahebi Mohammadi P; Pantel K
Int J Cancer; 2021 Feb; 148(3):528-545. PubMed ID: 32683679
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy: novel technologies and clinical applications.
Reimers N; Pantel K
Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
Cells; 2019 May; 8(6):. PubMed ID: 31142037
[TBL] [Abstract][Full Text] [Related]
17. Circulating biomarkers for early detection and clinical management of colorectal cancer.
Marcuello M; Vymetalkova V; Neves RPL; Duran-Sanchon S; Vedeld HM; Tham E; van Dalum G; Flügen G; Garcia-Barberan V; Fijneman RJ; Castells A; Vodicka P; Lind GE; Stoecklein NH; Heitzer E; Gironella M
Mol Aspects Med; 2019 Oct; 69():107-122. PubMed ID: 31189073
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy for cancer diagnosis and screening - The promise and challenges.
Thorat MA
Ann Clin Biochem; 2019 Jul; 56(4):420-423. PubMed ID: 30971101
[No Abstract] [Full Text] [Related]
19. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
